DCX Prices $5M Registered Direct Offering at $0.21 with Aggressive Warrant Structure
DCX sits 18% above its 52-week low of $0.112 on elevated volume (10× avg).
Summary
DCX priced a $5M registered direct offering at $0.21 per share with warrants that could add up to 71.4M shares. The deal includes aggressive anti-dilution provisions tied to the pending 160-for-1 reverse split, and comes as the company faces a going-concern warning with no revenue from continuing operations.
Key Events · Financing and Capital Events · DCX
-
$5M Offering Priced at $0.21
23,809,530 Class A ordinary shares sold at $0.21 each for gross proceeds of $5,000,001.30, a steep discount to the $0.4401 last reported sale price on September 17, 2026.
-
Warrant Structure Adds 71.4M Share Overhang
Series A warrants (23.8M shares at $0.44, 5-year term) and Series B warrants (23.8M units at $0.21, 30-day term) could add up to 71,428,590 shares if fully exercised — nearly 20% of the 375.4M shares outstanding post-offering.
-
Anti-Dilution Reset Tied to Reverse Split
Both warrant series reset exercise prices to the lowest VWAP around share combination events, including the 160-for-1 reverse split approved September 3, 2026. With the stock at $0.1317, this reset could substantially increase warrant share counts.
-
Placement Agent Compensation
Maxim Group receives 7.0% cash fee ($350,000.09), 5.0% placement agent warrants (1,190,476 shares at $0.44), $50,000 expense reimbursement, and 7.0% of Series B warrant exercise proceeds.
Analysis · DCX · Manufacturing
DCX is raising $5 million at $0.21 per share — a steep discount to the $0.4401 last reported sale price on September 17, 2026 — with a warrant package that could add up to 71.4 million more shares. The Series A warrants carry a $0.44 exercise price with a 5-year term, while the Series B warrants expire in just 30 days at $0.21 per unit, creating near-term overhang. Critically, both warrant series contain anti-dilution provisions that reset the exercise price to the lowest VWAP around share combination events — including the pending 160-for-1 reverse split approved September 3, 2026. Given the stock trades at $0.1317 today, that reset could substantially increase the number of shares issuable on exercise. The company is burning cash with no revenue from continuing operations, a $189M net loss in H1 2026, and a going-concern warning in its 2025 annual report. This offering is survival capital, but the terms are expensive and the warrant overhang is significant.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.9% of the 1030 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DCX was trading at $0.13 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $46.6M. The 52-week trading range was $0.11 to $609.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.